Predict your next investment

HEALTHCARE | Drug Discovery
trevena.com

See what CB Insights has to offer

Stage

IPO | IPO

Total Raised

$129M

Date of IPO

1/31/2014

Market Cap

0.10B

Stock Price

0.60

Revenue

$0000 

About Trevena

Trevena is a clinical-stage pharmaceutical company focused on discovering and developing the next generation of G protein-coupled receptor (GPCR) targeted medicines. Despite the past success of GPCR drugs, there is a significant opportunity to enhance their therapeutic properties by specifically activating or deactivating selected receptor-mediated signals. Trevena's expertise lies in understanding which signaling pathways downstream of a GPCR are associated with beneficial versus adverse biological effects. The company utilizes that information to discover and optimize "biased ligands" which activate only the beneficial pathways to unlock new biology and avoid drug adverse effects.

Trevena Headquarter Location

955 Chesterbrook Blvd Suite 110

Wayne, Pennsylvania, 19087,

United States

610-354-8840

Latest Trevena News

DelveInsight Examines A Robust Pipeline For Postoperative Pain With More Than 55+ Pipeline Therapies As New And Influential Phar...

Jan 12, 2022

Innovations in Pain Management, Drug Discovery, and Development, as well as Increasing Awareness about surgical interventions, Rising investments in healthcare by governments, are some of the driving factors for the Postoperative Pain treatment market. Los Angeles, CA (GLOBE NEWSWIRE) - DelveInsight Examines a Robust Pipeline for Postoperative Pain with More than 55+ Pipeline Therapies as New and Influential Pharma Players Enter the Pain Management Landscape Innovations in Pain Management, Drug Discovery, and Development, as well as Increasing Awareness about surgical interventions, Rising investments in healthcare by governments, are some of the driving factors for the Postoperative Pain treatment market. DelveInsight’s ‘Postoperative Pain Pipeline Insight 2021’ report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Postoperative Pain pipeline domain. Some of the essential takeaways from the Postoperative Pain Pipeline report: DelveInsight’s Postoperative Pain Pipeline analysis depicts a robust space with 50+ active players working to develop 50+ pipeline treatment therapies. Some of the key pharmaceutical companies working to develop potential drug candidates to improve the Postoperative Pain treatment scenario include Vivozon, Grunenthal, Apsen Farmaceutica, Trevena, Haisco Pharmaceutical Group, Concentric Analgesics, Unither Pharmaceuticals, Formosa Pharmaceuticals, Cara Therapeutics, Taiwan Liposome Company, Adynxx, Teikoku Pharma USA, Cali Pharmaceuticals, ACADIA Pharmaceuticals, Nevakar, Cytogel, Mati Therapeutics, Allay therapeutics, SiteOne Therapeutics, NeurOp, Flexion Therapeutics, Hefei Cosource Pharmaceutical, Layerbio, Neumentum, Antibe Therapeutics, Serina Therapeutics, InSitu Biologics, PharmaTher, Bexson Biomedical, Hana Pharm, Expanesthetics, Algomedix Inc, AmacaThera, Andros Pharmaceuticals, Heron Therapeutics, Endo Pharmaceuticals, Mylan, Camurus, PainReform, Jiangsu HengRui Medicine, Polypid, Pharmaleads, Nuance Biotech Co, PharmaTher, TSRL, Neumentum Inc., Janssen Pharmaceutica NV, McNeil Consumer Pharmaceuticals Co, and many others. Essential Postoperative Pain pipeline therapies such as VVZ-149, Qutenza, TRV130, HSK21542, CA-008, SVT-15473, APP13007, CR845, TLC590, PRF110, OCS-01, MR-107A-01,JNJ-10450232, HR18042, CPL- 01, ACP-044, NVK-009, CYT 1010, XG005, CAM2048, ATX-101, ST 2427, NP 10679, ND-340, FX301,HYR-PB21, LC-400, NTM-001, RHN-002, ATB-352, SER-227, INSB200, BB106, ATX-201, AMT-143, APC401, and others are under development in different phases of clinical trials. In June 2021, Formosa Pharmaceuticals and China Grand Pharma announced that they have entered into an exclusive licensing agreement for the development and commercialization of Formosa’s APP13007 in the territory defined by Mainland China, Hong Kong, and Macau. APP13007, derived from Formosa’s proprietary nanoparticle formulation platform, is a novel ophthalmic application of one of the most potent known corticosteroids for the treatment of inflammation and pain after cataract surgery. In October 2021, Neumentum entered into a license agreement with Nuance Biotech Co. Ltd, a China based specialty pharmaceutical company, providing Nuance with the exclusive rights to develop and commercialize Neumentum’s novel ketorolac for IV infusion (NTM-001) in China. In January 2021, IACTA Pharmaceuticals, Inc. and Pharmaleads announced they that have entered into licensing agreements, with IACTA acquiring global rights to Pharmaleads' Dual Enkephalinase Inhibitors (DENKI®), a novel class of non-opioid compounds for the treatment of acute and chronic ocular pain. In June 2021, PharmaTher and TSRL entered into a Co-Development Agreement to jointly develop a microneedle array patch with the aim to control the manufacturing and supply of microneedle patches for the Companies respective clinical and commercial drug programs. PharmaTher and TSRL share the commitment to commercialize a patented hydrogel-forming microneedle patch delivery technology licensed from Queens University of Belfast. In November 2018, The Food and Drug Administration (FDA) announced fast track status for VVZ-149 (Vivozon Inc), a non-opioid, non-NSAID analgesic for the treatment of pain. In September 2018, Concentric Analgesics announced that it had received Breakthrough Therapy designation from the US FDA for CA-008 in post-surgical pain. In October 2019, Neumentum Inc. announced that it has entered into a global licensing agreement with Janssen Pharmaceutica NV and McNeil Consumer Pharmaceuticals Co., both part of the Johnson & Johnson Family of Companies, for the rights to a novel oral analgesic, JNJ-10450232, plus a portfolio of backup compounds. Neumentum wants to take JNJ-10450232, which it describes as neither an opioid nor a nonsteroidal anti-inflammatory drug, forward in the treatment of moderate to moderately severe acute pain. The deal, financial details of which were not disclosed. The agreement covers an asset that came through a Phase II pain trial in 2015 only to stall following the completion of the study. Request a sample and discover more about the report offerings @ Postoperative Pain Emerging Therapies The Postoperative Pain pipeline report lays down detailed profiles of the pipeline assets, comparative analysis of clinical and non-clinical stage Postoperative Pain products, inactive and dormant assets, comprehensive assessment of driving and restraining factors, as well as the opportunities and risks in the Postoperative Pain pipeline landscape. Postoperative Pain Overview Postoperative pain is an anticipated and temporary pain that occurs following grafting procedures or burn excision. Postoperative pain is experienced by the vast majority of patients who undergo surgical procedures. Control of postoperative pain plays an essential role in facilitating a patient’s recovery to normal function and reduces the incidence of adverse physiologic and psychological effects associated with acute, uncontrolled pain. Postoperative pain control may be achieved by a variety of mechanisms, including (but not limited to) the use of pharmacological agents and interventional techniques. Postoperative pain can be divided into acute pain and chronic pain. Acute pain is experienced immediately after surgery (up to 7 days) and pain that lasts more than 3 months after the injury is considered to be chronic pain. Acute and chronic pain can arise from cutaneous, deep somatic or visceral structures. Find out more about the disease and recent developments @ Postoperative Pain Pipeline Assessment Postoperative Pain Pipeline Drugs Coverage: Global Major Players: Vivozon, Grunenthal, Apsen Farmaceutica, Trevena, Haisco Pharmaceutical Group, Concentric Analgesics, Unither Pharmaceuticals, Formosa Pharmaceuticals, Cara Therapeutics, Taiwan Liposome Company, Adynxx, Teikoku Pharma USA, Cali Pharmaceuticals, ACADIA Pharmaceuticals, Nevakar, Cytogel, Mati Therapeutics, Allay therapeutics, SiteOne Therapeutics, NeurOp, Flexion Therapeutics, Hefei Cosource Pharmaceutical, Layerbio, Neumentum, Antibe Therapeutics, Serina Therapeutics, InSitu Biologics, PharmaTher, Bexson Biomedical, Hana Pharm, Expanesthetics, Algomedix Inc, AmacaThera, Andros Pharmaceuticals, and many others Key Postoperative Pain Pipeline Therapies: VVZ-149, Qutenza, TRV130, HSK21542, CA-008, SVT-15473, APP13007, CR845, TLC590, PRF110, OCS-01, MR-107A-01,JNJ-10450232, HR18042, CPL- 01, ACP-044, NVK-009, CYT 1010, XG005, CAM2048, ATX-101, ST 2427, NP 10679, ND-340, FX301,HYR-PB21, LC-400, NTM-001, RHN-002, ATB-352, SER-227, INSB200, BB106, ATX-201, AMT-143, APC401, and others Dive deep into rich insights for emerging therapies and assessment, visit @ Postoperative Pain Emerging Therapies Table of Contents

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Trevena

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Trevena is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,532 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Trevena Patents

Trevena has filed 30 patents.

The 3 most popular patent topics include:

  • Analgesics
  • Phenols
  • G protein coupled receptors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/1/2017

8/3/2021

G protein coupled receptors, Phenols, Amines, Analgesics, Pyridines

Grant

Application Date

12/1/2017

Grant Date

8/3/2021

Title

Related Topics

G protein coupled receptors, Phenols, Amines, Analgesics, Pyridines

Status

Grant

Trevena Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Trevena Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.